Cassava Sciences Inc (SAVA) - Sunday, Sep 29, 2024

• Cassava Sciences is deemed largely worthless with a cult-like retail investor base, making it an attractive target for shorting.
• Their sole asset, simufilam, aims to address Alzheimer's by restoring the shape of misfolded filamin A, but this approach has raised doubts.
• Dr. Hoau-Yan Wang, a longtime scientific collaborator, is indicted for fraud related to grants associated with their trials, raising questions about the company's credibility, alongside scrutiny on CEO Remi Barbier.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.